NCT05260125 Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients
| NCT ID | NCT05260125 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Abant Izzet Baysal University |
| Condition | Hemiplegia |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-03-15 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2022-03-15 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the effectiveness of ultrasound-guided and non-guided suprascapular nerve block in the treatment of patients with hemiplegic shoulder pain, which is one of the most common post-stroke complications.
Eligibility Criteria
Inclusion Criteria: * Having hemiplegic shoulder pain for 3 months * Visual analogue scale score \> 3 during passive shoulder joint movement on the hemiplegic side Exclusion Criteria: * Mini mental test score \<24 * Patients with uncontrolled diabetes, coagulopathy * Botulinum toxin administration in the past six months, * Any injection in the shoulder region in the last six months * Having hypersensitivity to injection agents
Contact & Investigator
Serdar kılınç
PRINCIPAL INVESTIGATOR
Abant Izzet Baysal University
Frequently Asked Questions
Who can join the NCT05260125 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 75 Years, studying Hemiplegia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05260125 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05260125 currently recruiting?
Yes, NCT05260125 is actively recruiting participants. Contact the research team at drserdarkilinc@hotmail.com for enrollment information.
Where is the NCT05260125 trial being conducted?
This trial is being conducted at Bolu, Turkey (Türkiye).
Who is sponsoring the NCT05260125 clinical trial?
NCT05260125 is sponsored by Abant Izzet Baysal University. The principal investigator is Serdar kılınç at Abant Izzet Baysal University. The trial plans to enroll 50 participants.